Dosing patients with gene transfer vectors for the treatment of lung disease likely will require intraluminal delivery strategies. We hypothesize that vector delivery via this route will confront two major barriers prior to any potential vector interaction with a cell surface receptor: (1) the transported mucus layer; (2) the cell surface tethered mucin/glycocalyx layer. Surprisingly little is known about the relative efficiencies (defined as percent of delivered vectors reaching epithelial cell surfaces) of the two principal delivery modes (aerosolization; lavage) for topical airways vector delivery. Thus, prior to further human clinical studies, we propose first to quantitate the barriers to vector penetration to the epithelial cell surface afforded by mucus clearance after aerosol vs. lavage vector delivery. Because we speculate that clearance of topically delivered vector will be rapid, and hence delivery to epithelial cell surfaces inefficient, we propose strategies to increase the efficiency for both aerosol and lavage administration, and use these data to select an optimal delivery system for our mouse studies (see below). Next, we hypothesize that vectors that escape mucus clearance will confront a second barrier, the cell surface -glycocalyx. Thus, we propose to identify the components of the glycocalyx that contribute to the functional barrier to gene transfer and design strategies to abrogate these barriers in studies with well-differentiated and freshly excised human airway epithelial preparations. The concepts and strategies to abrogate the barrier function of the glycocalyx, particularly the contribution of the tethered mucins MUC1 and MUC4, will be extended to in vivo conditions using transgenic mice. Employing a defined target (GPI-CAR) for adenovirus mediated gene transfer in the apical membrane of airway epithelia in transgenic mice, we will systematically explore the role of the glycocalyx as a barrier to gene transfer in wild-type mice and mice deficient in MUC1 and MUC4.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL066973-01A1
Application #
6533329
Study Section
Heart, Lung, and Blood Program Project Review Committee (HLBP)
Project Start
2001-09-30
Project End
2006-07-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Monahan, Paul E; Sun, Junjiang; Gui, Tong et al. (2015) Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 26:69-81
Monahan, P E (2015) Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost 13 Suppl 1:S151-60
Piacentino 3rd, Valentino; Milano, Carmelo A; Bolanos, Michael et al. (2012) X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. Hum Gene Ther 23:635-46
Kantor, Boris; Bayer, Matthew; Ma, Hong et al. (2011) Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector. Mol Ther 19:547-56
Cockrell, Adam S; van Praag, Henriette; Santistevan, Nicholas et al. (2011) The HIV-1 Rev/RRE system is required for HIV-1 5' UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles. Retrovirology 8:51
Monahan, Paul E; Lothrop, Clinton D; Sun, Junjiang et al. (2010) Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther 18:1907-16
Li, C; Hirsch, M; Carter, P et al. (2009) A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther 16:43-51
Gui, T; Reheman, A; Ni, H et al. (2009) Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 7:1843-51
Li, Chengwen; Goudy, Kevin; Hirsch, Matt et al. (2009) Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A 106:10770-4
Kantor, Boris; Ma, Hong; Webster-Cyriaque, Jennifer et al. (2009) Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci U S A 106:18786-91

Showing the most recent 10 out of 38 publications